In 2018, the results of a phase I trial of a combination of cobolimab, an anti-TIM-3 antibody, and dostarlimab, an anti-PD-1 antibody, showed that in 25 NSCLC patients who developed resistance to anti-PD-1 antibodies, cobolimab combined with dostarlimab produced a response in 3 of 20 evaluable patients; hence, further development of this combination therapy is expected to overcome ICI resistance (107). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.